What is Lumenis?
Founded in 1966 and headquartered in Hesse, Germany, Lumenis specializes in the development and commercialization of sophisticated energy-based technologies. The company's portfolio is engineered to address critical needs in skin, body, and eye care, featuring flagship platforms such as Trilift, Optilight, and the Stellar M22. By integrating high-precision engineering with clinical efficacy, Lumenis maintains a competitive edge in the aesthetic and ophthalmic medical device markets. Its long-term operational history serves as a testament to its ability to adapt to evolving medical standards and technological advancements in non-invasive therapeutic procedures.
How much funding has Lumenis raised?
Lumenis has raised a total of $195M across 2 funding rounds:
Private Equity
$120M
Stock Offering
$75M
Private Equity (2006): $120M with participation from XT Group
Stock Issuance/Offering (2014): $75M, investors not publicly disclosed
Key Investors in Lumenis
XT Group
XT Group is a global holding company based in Israel that manages a diverse portfolio of subsidiaries, including significant interests in shipping and high-tech sectors, with a focus on sustainable growth and long-term strategic investment.
Undisclosed Institutional Investor
An undisclosed investor participating in the funding round, providing essential capital to support the company's ongoing research and development initiatives.
Undisclosed Private Equity Partner
An undisclosed investor participating in the funding round, specializing in private equity and enterprise-level growth financing.
What's next for Lumenis?
The infusion of capital positions Lumenis to accelerate its research and development pipeline, particularly in the refinement of its digital and energy-based treatment modalities. As the company transitions through this major enterprise-level funding phase, the focus will likely shift toward expanding its international footprint and enhancing the digital integration of its existing product suite. By leveraging its established reputation and deep technical expertise, Lumenis is well-positioned to capture additional market share in the high-growth aesthetic and ophthalmology sectors, ensuring sustained long-term value for stakeholders and improved patient outcomes through continued innovation.
See full Lumenis company page
